Ester Banque has been named executive vice president and president of U.S. operations, for the Zoetis, effective July 10, 2023.
Banque brings to the company over 30 years of experience in health sciences with top tier pharmaceutical companies. She will be a member of the Zoetis executive team and report to Chief Executive Officer Kristin Peck.
“We are excited to welcome Ester Banque to lead our U.S. business after a thoughtful and extensive search process,” said Peck. “We were impressed by Ester’s diverse, global experience, leadership of high performing teams, and above-market growth achievements. She is a passionate, purpose-driven leader who brings diverse experience and an impressive track record of driving results, which will promote Zoetis’ long-term sustainable growth.”
In this role, Banque will have responsibility for the company’s U.S. commercial operations, continuing to broaden and expand the company’s key franchises and shape the market for future innovation - providing exceptional experiences for companion animal and livestock customers.
“I am proud to join Zoetis and be part of an organization that is built on the foundation of a purpose-driven culture, powered by an innovative, robust pipeline and high-performing teams. This new challenge will allow me to further expand my commitment to healthcare, and advance Zoetis’ purpose ‘to nurture our world and humankind by advancing care for animals. I am looking forward to building on Zoetis’ leadership in animal health and capitalizing on opportunities to make a positive impact on our customers, colleagues and communities,” said Banque.
In connection with her appointment, William (“Chip”) Dorsey, interim Head of U.S. Operations since February 2023, will continue in his finance leadership role and be a resource to Banque as she onboards.
“On behalf of the Zoetis Executive Team, I also want to thank Chip for his leadership over the past five months,” said Peck.
About Ester Banque
Most recently, Banque has served as senior vice president and general manager of Bristol Myers-Squibb’s U.S. Hematology & Cell Therapy Business, where she led the transformation of a portfolio -- from major losses of patent exclusivity to accelerating the launch of five products -- while managing a $14 billion P&L for the company. Before joining Bristol Myers-Squibb, Ester she 25 years at Novartis where she held a variety of senior commercial positions and spearheaded the most successful product launch in the company’s history, before taking on the role of general manager of Oncology, Germany.
